E

Enanta Pharmaceuticals

D
ENTA
USD
-0.16
(-1.3877%)
Market Closed
1,700.00
Volume
-5.135
EPS
-
Div Yield
-2.086239
P/E
240,914,052.27
Market Cap
Today
-1.3877%
1 Week
1.067%
1 Month
-1.729%
6 Months
-13.073%
12 Months
24.739%
Year To Date
20.957%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
A
AXSM
-0.28
(-0.3079%)
USD
A
ARWR
0.055
(0.2579%)
USD
A
ASND
-2.7
(-2.089%)
USD
BMY
BMY
-0.57
(-1.0313%)
USD
A
ALX
-5.98
(-2.5152%)
USD
A
APLS
-0.11
(-0.3809%)
USD
C
CRVS
-0.01
(-0.1135%)
USD
F
FLXN
(%)
USD
M
MCRB
-0.0359
(-4.7758%)
USD

Title:
Enanta Pharmaceuticals

Sector:
Healthcare
Industry:
Biotechnology
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
Do you need help or have a question?
Contact Us